BioSpace

FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals

Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...

Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI)

In early December 2025, Denali Therapeutics announced a US$275 million synthetic royalty funding agreement with Royalty Pharma tied to future worldwide net sales of its investigational Hunter syndrome ...
Zacks Investment Research on MSN

Denali enters into a $275M funding deal with Royalty Pharma

Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
GlobalData on MSN

Denali makes $275m funding agreement with Royalty Pharma

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
Fierce Biotech

FDA slaps hold on Denali's plans for phase 1 rare disease trial

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.
Fierce Biotech

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...